Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 11/20 | 1.00 |
| ▸ | EYA3 | Q99504 | 6/20 | 1.00 |
| ▸ | TTR | P02766 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.75 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | PGR | P06401 | 2/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.75 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.75 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | EYA2 | O00167 | 1/20 | 0.75 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.75 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
| ▸ | USP2 | O75604 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25814817 | 0.91 | SLC22A12 (0.84) | SLC22A12EYA3TTRCYP2C19CYP2C9 | |
| SCHEMBL30357404 | 0.90 | SLC22A12 (0.81) | SLC22A12EYA3TTRCYP2C19CYP2C9 | |
| SCHEMBL1287499 | 0.90 | SLC22A12 (1.00) | SLC22A12EYA3TTRCYP2C19CYP2C9 | |
| SCHEMBL15698041 | 0.89 | SLC22A12 (0.80) | SLC22A12EYA3TTRCYP2C19CYP2C9 | |
| SCHEMBL30258768 | 0.89 | SLC22A12 (0.80) | SLC22A12EYA3TTRCYP2C19CYP2C9 | |
| SCHEMBL26809272 | 0.88 | SLC22A12 (0.78) | SLC22A12EYA3TTRCYP2C19CYP2C9 | |
| SCHEMBL25815047 | 0.88 | SLC22A12 (0.78) | SLC22A12EYA3TTRCYP2C19CYP2C9 | |
| SCHEMBL20280887 | 0.88 | SLC22A12 (0.78) | SLC22A12EYA3TTRCYP2C19CYP2C9 | |
| Benzbromarone SCHEMBL19205474 | 0.86 | SLC22A12 (1.00) | SLC22A12EYA3TTRCYP2C19CYP2C9 | |
| Benzbromarone SCHEMBL29361528 | 0.86 | SLC22A12 (1.00) | SLC22A12EYA3TTRCYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023058975-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING HSP47 INCLUDING BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE | (주)이노보테라퓨틱스 | 2023-04-13 | — | — | WO | claimed |
| US-20230218563-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ARTHROSI THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218563-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ARTHROSI THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2023098872-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023058975-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING HSP47 INCLUDING BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE | (주)이노보테라퓨틱스 | 2023-04-13 | — | — | WO | disclosed |
| WO-2021252630-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ARTHROSI THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210130312-A1 | INHIBITORS OF EYA3-PROTEIN TYROSINE PHOSPHATASE IN DNA DAMAGE REPAIR SIGNALING OF PULMONARY ARTERIAL HYPERTENSION | CHILDRENS HOSPITAL MED CT (US) | 2021-05-06 | — | — | US | disclosed |
| WO-2020232156-A1 | COMPOUND FOR TREATING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020118113-A1 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020118114-A1 | METHODS FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | ARTHROSI THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20140128460-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-05-08 | — | — | US | disclosed |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| WO-2012048058-A2 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2012-04-12 | — | — | WO | disclosed |
| US-7521570-B2 | Medicinal compositions containing 6-hydroxybenzbromarone or salts thereof | TORLI PHARMACEUTICAL CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-7521570-B2 | Medicinal compositions containing 6-hydroxybenzbromarone or salts thereof | TORLI PHARMACEUTICAL CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-7521570-B2 | Medicinal compositions containing 6-hydroxybenzbromarone or salts thereof | TORLI PHARMACEUTICAL CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-20070185195-A1 | Medicinal compositions containing 6-hydroxybenzbromarone or salts thereof | HUMAN CELL SYSTEMS, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185195-A1 | Medicinal compositions containing 6-hydroxybenzbromarone or salts thereof | HUMAN CELL SYSTEMS, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185195-A1 | Medicinal compositions containing 6-hydroxybenzbromarone or salts thereof | HUMAN CELL SYSTEMS, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| EP-1767531-A1 | MEDICINAL COMPOSITIONS CONTAINING 6-HYDROXYBENZBROMARONE OR SALTS THEREOF | Torii Pharmaceutical Co., Ltd. (JP) | 2007-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128460-A1 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE | EYA2, EYA3, PTPRO | SLC22A12 3718/4885EYA3 2/4885TTR 1815/4885 |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | SLCO2B1, SLCO2A1, SLC10A6 | SLC22A12 19/4885EYA3 4828/4885TTR 1944/4885 |
| US-20210130312-A1 | INHIBITORS OF EYA3-PROTEIN TYROSINE PHOSPHATASE IN DNA DAMAGE REPAIR SIGNALING OF PULMONARY ARTERIAL HYPERTENSION | EYA3, EYA2, LIG3 | SLC22A12 4469/4885EYA3 1/4885TTR 3493/4885 |
| US-20070185195-A1 | Medicinal compositions containing 6-hydroxybenzbromarone or salts thereof | XDH, UGT1A6, SLC10A1 | SLC22A12 98/4885EYA3 2508/4885TTR 1302/4885 |
| US-20230218563-A1 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | ATP6V1B1, REN, CYP27B1 | SLC22A12 620/4885EYA3 3141/4885TTR 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.